Acadia expects more than $1B in sales for 2025

Ascending sales graph on blackboard

akinbostanci/iStock via Getty Images

  • Acadia Pharmaceuticals (NASDAQ:ACAD) said that it expects to bring in product revenue of more than $1B in 2025 from sales of Nuplazid (pimavanserin) and Daybue (trofinetide).
  • In Q3, the latest quarter for which data is available, Nuplazid brought in $159.2M in revenue, while Daybue

Leave a Reply

Your email address will not be published. Required fields are marked *